CIENCIASMEDICASNEWS: Prolia (denosumab) by Amgen: Drug Safety Communication - FDA Investigating Risk of Severe Hypocalcemia in Patients on Dialysis | FDA

miércoles, 23 de noviembre de 2022

Prolia (denosumab) by Amgen: Drug Safety Communication - FDA Investigating Risk of Severe Hypocalcemia in Patients on Dialysis | FDA

Prolia (denosumab) by Amgen: Drug Safety Communication - FDA Investigating Risk of Severe Hypocalcemia in Patients on Dialysis | FDA

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)